Tricuspid regurgitation pressure gradient identifies prognostically relevant worsening renal function in acute heart failure.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
22 01 2021
Historique:
received: 30 10 2019
revised: 31 12 2019
accepted: 11 02 2020
pubmed: 12 3 2020
medline: 5 8 2021
entrez: 12 3 2020
Statut: ppublish

Résumé

Not all worsening renal function (WRF) during heart failure treatment is associated with a poor prognosis. However, a metric capable providing a prognosis of relevant WRF has not been developed. Our aim was to evaluate if a change in tricuspid regurgitation pressure gradient (TRPG) could discriminate prognostically relevant and not relevant WRF in patients with acute heart failure (AHF). We examined 809 consecutive hospitalized patients with heart failure (78 ± 12 years, 54% male). WRF was defined as an increase in creatinine >0.3 mg and ≥25% from admission to discharge. TRPG was measured at admission and before discharge using echocardiography. The primary outcome was all-cause death within 1-year after discharge. Patients were classified as follows for analysis: no WRF and no TRPG increase (n = 523); no WRF and TRPG increase (no WRF with iTRPG, n = 170); WRF and no TRPG increase (WRF without iTRPG, n = 90); and WRF and TRPG increase (WRF with iTRPG, n = 26). A change in TRPG weakly but significantly correlated to a change in haemoglobin and haematocrit, a percent decrease in brain natriuretic peptide, and body weight reduction during the index period of hospitalization. All-cause mortality within 1 year was higher in patients with WRF and iTRPG, compared to the other three groups (P = 0.026). On Cox regression analysis, only WRF with iTRPG was associated with higher mortality (hazard ratio 4.24, P = 0.001), even after adjustment for other confounders. An increase in TRPG may provide a marker to identify prognostically relevant WRF in patients with AHF.

Identifiants

pubmed: 32157273
pii: 5802451
doi: 10.1093/ehjci/jeaa035
doi:

Substances chimiques

Natriuretic Peptide, Brain 114471-18-0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-209

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Kazuto Hayasaka (K)

Department of Cardiology, Kameda Medical Center, 929 Higashi-cho, Kamogawa city, Chiba 296-0041, Japan.
Department of Cardiology, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, Tokyo 190-0014, Japan.
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Yuya Matsue (Y)

Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Department of Cardiovascular Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.

Takahiro Okumura (T)

Department of Cardiology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan.

Keisuke Kida (K)

Department of Pharmacology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae, Kawasaki 216-8511, Japan.

Shogo Oishi (S)

Department of Cardiology, Himeji Cardiovascular Center, 520, Saisho-ko, Himeji, Hyogo 670-0981, Japan.

Eiichi Akiyama (E)

Division of Cardiology, Yokohama City University Medical Center, 4-57, Urafunecho, Minami-ku, Yokohama 232-0024, Japan.

Satoshi Suzuki (S)

Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.

Masayoshi Yamamoto (M)

Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.

Akira Mizukami (A)

Department of Cardiology, Kameda Medical Center, 929 Higashi-cho, Kamogawa city, Chiba 296-0041, Japan.

Kenji Yoshioka (K)

Department of Cardiology, Kameda Medical Center, 929 Higashi-cho, Kamogawa city, Chiba 296-0041, Japan.

Shunsuke Kuroda (S)

Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.

Nobuyuki Kagiyama (N)

Department of Cardiology, The Sakakibara Heart Institute of Okayama, 2-5-1 Nakai-Cho, Kita-ku, Okayama 700-0804, Japan.

Tetsuo Yamaguchi (T)

Department of Cardiology, Cardiovascular Center, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan.

Tetsuo Sasano (T)

Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH